Nasal vaccination with N-trimethyl chitosan and PLGA based nanoparticles: nanoparticle characteristics determine quality and strength of the antibody response in mice against the encapsulated antigen.

Nasal vaccination is a promising, needle-free alternative to classical vaccination. Nanoparticulate delivery systems have been reported to overcome the poor immunogenicity of nasally administered soluble antigens, but the characteristics of the ideal particle are unknown. This study correlates differences in physicochemical characteristics of nanoparticles to their adjuvant effect, using ovalbumin (OVA)-loaded poly(lactic-co-glycolic acid) nanoparticles (PLGA NP), N-trimethyl chitosan (TMC) based NP (TMC NP) and TMC-coated PLGA NP (PLGA/TMC NP). PLGA NP and PLGA/TMC NP were prepared by emulsification/solvent extraction and TMC NP by ionic complexation. The NP were characterized physicochemically. Their toxicity and interaction with and stimulation of monocyte derived dendritic cells (DC) were tested in vitro. Furthermore, the residence time and the immunogenicity (serum IgG titers and secretory IgA levels in nasal washes) of the nasally applied OVA formulations were assessed in Balb/c mice. All NP were similar in size, whereas only PLGA NP carried a negative zeta potential. The NP were non-toxic to isolated nasal epithelium. Only TMC NP increased the nasal residence time of OVA compared to OVA administered in PBS and induced DC maturation. After i.m. administration all NP systems induced higher IgG titers than OVA alone, PLGA NP and TMC NP being superior to PLGA/TMC NP. Nasal immunization with the slow antigen releasing particles, PLGA NP and PLGA/TMC NP, did not induce detectable antibody titers. In contrast, nasal immunization with the positively charged, fast antigen releasing TMC NP led to high serum antibody titers and sIgA levels. In conclusion, particle charge and antigen release pattern of OVA-loaded NP has to be adapted to the intended route of administration. For nasal vaccination, TMC NP, releasing their content within several hours, being mucoadhesive and stimulating the maturation of DC, were superior to PLGA NP and PLGA/TMC NP which lacked some or all of these characteristics.

[1]  F. Szoka,et al.  Effect of liposome encapsulation on antigen presentation in vitro. Comparison of presentation by peritoneal macrophages and B cell tumors. , 1989, Journal of immunology.

[2]  E. Hundt,et al.  Tetanus Toxoid Loaded Nanoparticles from Sulfobutylated Poly(Vinyl Alcohol)-Graft-Poly(Lactide-co-Glycolide): Evaluation of Antibody Response After Oral and Nasal Application in Mice , 2001, Pharmaceutical Research.

[3]  M. Baca-Estrada,et al.  Induction of mucosal immune responses by administration of liposome-antigen formulations and interleukin-12. , 1999, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[4]  Frederik Maes,et al.  High‐speed digital imaging method for ciliary beat frequency measurement , 2005, The Journal of pharmacy and pharmacology.

[5]  Y. Barenholz,et al.  A new intranasal influenza vaccine based on a novel polycationic lipid--ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice. , 2006, Vaccine.

[6]  J L Pedraz,et al.  Size dependent immune response after subcutaneous, oral and intranasal administration of BSA loaded nanospheres. , 2002, Vaccine.

[7]  H. Junginger,et al.  N-trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination: biological properties and immunogenicity in a mouse model. , 2007, Vaccine.

[8]  Tao Wang,et al.  Modulation of surface charge, particle size and morphological properties of chitosan-TPP nanoparticles intended for gene delivery. , 2005, Colloids and surfaces. B, Biointerfaces.

[9]  J. Pedraz,et al.  Influence of dose and immunization route on the serum Ig G antibody response to BSA loaded PLGA microspheres. , 2002, Vaccine.

[10]  W. Hennink,et al.  Conjugation of ovalbumin to trimethyl chitosan improves immunogenicity of the antigen. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[11]  S. Vyas,et al.  Strong systemic and mucosal immune responses to surface-modified PLGA microspheres containing recombinant hepatitis B antigen administered intranasally. , 2006, Vaccine.

[12]  W. Hennink,et al.  Relationship between structure and adjuvanticity of N,N,N-trimethyl chitosan (TMC) structural variants in a nasal influenza vaccine. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[13]  N. Mishra,et al.  Plasmid DNA loaded chitosan nanoparticles for nasal mucosal immunization against hepatitis B. , 2008, International journal of pharmaceutics.

[14]  P. Augustijns,et al.  Effect of preservatives on ciliary beat frequency in human nasal epithelial cell culture: single versus multiple exposure. , 2007, International journal of pharmaceutics.

[15]  C. van Nostrum,et al.  Preparation and characterization of protein loaded microspheres based on a hydroxylated aliphatic polyester, poly(lactic-co-hydroxymethyl glycolic acid). , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[16]  W. Jiskoot,et al.  Mechanistic study of the adjuvant effect of biodegradable nanoparticles in mucosal vaccination. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[17]  K. Melber,et al.  Intranasal immunization with recombinant antigens associated with new cationic particles induces strong mucosal as well as systemic antibody and CTL responses. , 2002, Vaccine.

[18]  A. Alshamsan,et al.  Enhanced antigen-specific primary CD4+ and CD8+ responses by codelivery of ovalbumin and toll-like receptor ligand monophosphoryl lipid A in poly(D,L-lactic-co-glycolic acid) nanoparticles. , 2007, Journal of biomedical materials research. Part A.

[19]  Elly van Riet,et al.  Efficient induction of immune responses through intradermal vaccination with N-trimethyl chitosan containing antigen formulations. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[20]  Ira Mellman,et al.  Cell biology of antigen processing in vitro and in vivo. , 2005, Annual review of immunology.

[21]  S. Rossi,et al.  Nanoparticles based on N-trimethylchitosan: evaluation of absorption properties using in vitro (Caco-2 cells) and ex vivo (excised rat jejunum) models. , 2007, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[22]  W. Jiskoot,et al.  2 Rational design of nasal vaccines , 2011 .

[23]  Brian R. Sloat,et al.  Strong Mucosal and Systemic Immunities Induced by Nasal Immunization with Anthrax Protective Antigen Protein Incorporated in Liposome–Protamine–DNA Particles , 2005, Pharmaceutical Research.

[24]  B. Gander,et al.  The preservation of phenotype and functionality of dendritic cells upon phagocytosis of polyelectrolyte-coated PLGA microparticles. , 2007, Biomaterials.

[25]  H. Junginger,et al.  Preparation and characterization of protein-loaded N-trimethyl chitosan nanoparticles as nasal delivery system. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[26]  M. Alonso,et al.  Nanoparticles as carriers for nasal vaccine delivery , 2005, Expert review of vaccines.

[27]  Wim E Hennink,et al.  Chitosan-based delivery systems for protein therapeutics and antigens. , 2010, Advanced drug delivery reviews.

[28]  V. Préat,et al.  Intranasal immunization against influenza virus using polymeric particles. , 1999, Journal of biomaterials science. Polymer edition.

[29]  J. Schiller,et al.  Humoral and cellular immune responses to airway immunization of mice with human papillomavirus type 16 virus-like particles and mucosal adjuvants. , 2007, Antiviral research.

[30]  H. Benson,et al.  Pharmaceutical aspects of intranasal delivery of vaccines using particulate systems. , 2009, Journal of pharmaceutical sciences.

[31]  O. Corrigan,et al.  Quantifying drug release from PLGA nanoparticulates. , 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[32]  K. Haruma,et al.  Uptake of microparticles into the epithelium of human nasopharyngeal lymphoid tissue , 2006, Medical Molecular Morphology.

[33]  W. Hennink,et al.  Synthesis, characterization and in vitro biological properties of O-methyl free N,N,N-trimethylated chitosan. , 2008, Biomaterials.

[34]  Arvind K. Jain,et al.  Evaluation of Mucoadhesive PLGA Microparticles for Nasal Immunization , 2010, The AAPS Journal.

[35]  R. Read,et al.  Effective nasal influenza vaccine delivery using chitosan. , 2005, Vaccine.

[36]  A. Vila,et al.  PLA-PEG particles as nasal protein carriers: the influence of the particle size. , 2005, International journal of pharmaceutics.

[37]  J. Cassiman,et al.  Ciliogenesis and coordinated ciliary beating in human nasal epithelial cells cultured in vitro. , 1989, Acta oto-rhino-laryngologica Belgica.

[38]  S. Sorichter,et al.  Immune responses in the airways by nasal vaccination with systemic boosting against Pseudomonas aeruginosa in chronic lung disease. , 2009, Vaccine.

[39]  B. Gander,et al.  Biodegradable microspheres alone do not stimulate murine macrophages in vitro, but prolong antigen presentation by macrophages in vitro and stimulate a solid immune response in mice. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[40]  M. Kipper,et al.  Polysaccharide-based polyelectrolyte complex nanoparticles from chitosan, heparin, and hyaluronan. , 2009, Biomacromolecules.

[41]  W. Jiskoot,et al.  Role of trimethylated chitosan (TMC) in nasal residence time, local distribution and toxicity of an intranasal influenza vaccine. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[42]  S Senel,et al.  Mono-N-carboxymethyl chitosan (MCC) and N-trimethyl chitosan (TMC) nanoparticles for non-invasive vaccine delivery. , 2008, International journal of pharmaceutics.

[43]  W. Jiskoot,et al.  Physicochemical and Immunological Characterization of N,N,N-Trimethyl Chitosan-Coated Whole Inactivated Influenza Virus Vaccine for Intranasal Administration , 2009, Pharmaceutical Research.

[44]  Y. Waeckerle‐Men,et al.  PLGA microspheres for improved antigen delivery to dendritic cells as cellular vaccines. , 2005, Advanced drug delivery reviews.

[45]  V. Kanchan,et al.  Memory antibody response from antigen loaded polymer particles and the effect of antigen release kinetics. , 2009, Biomaterials.